Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 3, Pages 832
Publisher
MDPI AG
Online
2022-02-07
DOI
10.3390/cancers14030832
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
- (2021) Nasser H. Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
- (2021) J. Han et al. Journal of Thoracic Oncology
- 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
- (2021) H.A. Yu et al. ANNALS OF ONCOLOGY
- First‐Line Osimertinib in Patients with EGFR ‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
- (2021) Martina Lorenzi et al. ONCOLOGIST
- Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
- (2021) Filippo Papini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
- (2021) Egbert F Smit et al. Future Oncology
- Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
- (2021) Shun Lu et al. Journal of Thoracic Oncology
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- (2020) G.R. Oxnard et al. ANNALS OF ONCOLOGY
- Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward
- (2020) Umberto Malapelle et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- (2020) Yi-Long Wu et al. Lancet Respiratory Medicine
- A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
- (2020) Jin-Ji Yang et al. INVESTIGATIONAL NEW DRUGS
- Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer
- (2020) Mei-Mei Zheng et al. Journal of Thoracic Oncology
- Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer
- (2019) S. A. Laurie et al. Current Oncology
- SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.
- (2019) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Single and dual targeting of mutant EGFR with an allosteric inhibitor
- (2019) Ciric To et al. Cancer Discovery
- The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
- (2019) P.H. Patel et al. CLINICAL ONCOLOGY
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
- (2018) Peng Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
- (2017) Timothy A. Yap et al. EUROPEAN JOURNAL OF CANCER
- Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
- (2017) Tony S.K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer
- (2016) Keunchil Park et al. JAMA Oncology
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications
- (2013) David R. Gandara et al. Clinical Lung Cancer
- Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
- (2013) S. B. Goldberg et al. ONCOLOGIST
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
- (2012) Kenichi Nishie et al. Journal of Thoracic Oncology
- Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
- (2012) Kazuhiro Asami et al. LUNG CANCER
- Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
- (2012) Mizuki Nishino et al. LUNG CANCER
- Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
- (2010) S. Heon et al. CLINICAL CANCER RESEARCH
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started